Global Muscle Wasting Disorders Market Size was Anticipated at USD 21.86 Billion by 2035 | CAGR of 7.94%
Category: HealthcareGlobal Muscle Wasting Disorders Market Size was Anticipated at USD 21.86 Billion by 2035 | CAGR of 7.94%
According to a Research Report Published by Spherical Insights & Consulting, The Global Muscle Wasting Disorders Market Size is estimated to Grow from USD 9.43 Billion in 2024 to USD 21.86 Billion by 2035, at a CAGR of 7.94% during the forecast period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Muscle Wasting Disorders Market Size, Share, and COVID-19 Impact Analysis, By Disease Type (Muscular Dystrophy, Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis, and Others), By Treatment Modality (Drug Therapies, Gene Therapy, Physical Therapy and Rehabilitation, Supplements and Nutrition, and Others), By Mechanism of Action (Anti-inflammatory Agents, Muscle Growth Stimulators, Gene Editing Therapies, Immunomodulatory, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/muscle-wasting-disorders-market
The global muscle wasting disorders market refers to the healthcare sector that develops treatments and supportive therapies for conditions which lead to progressive muscle mass and strength loss such as muscular dystrophy and sarcopenia. Market growth is driven by three factors which include the rising aging population and increasing prevalence of neuromuscular diseases and growing healthcare awareness. Government initiatives which support rare disease research and orphan drug development are driving progress in treatment innovation. The development of new technologies such as gene therapy and biologics and precision medicine is enhancing both diagnostic procedures and treatment results. The combination of more clinical trials and increased biotechnology investment and better healthcare infrastructure in developing nations is providing the market with large growth opportunities.
The muscular dystrophy segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the disease type, the global muscle wasting disorders market is divided into muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, and others. Among these, the muscular dystrophy segment accounted for the largest share in 2024, and is anticipated to grow at a significant CAGR during the forecast period. This is because muscular dystrophy is widespread, requires ongoing treatment, and generates constant demand for specialized therapies, supportive care, and advanced solutions.
The drug therapies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.
Based on the treatment modality, the global muscle wasting disorders market is divided into drug therapies, gene therapy, physical therapy and rehabilitation, supplements and nutrition, and others. Among these, the drug therapies segment accounted for the highest market revenue in 2024, and is anticipated to grow at a significant CAGR during the forecast period because drug therapies offer easier accessibility, established clinical efficacy, and lower complexity compared to advanced treatments.
The muscle growth stimulators segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the mechanism of action, the global muscle wasting disorders market is divided into anti-inflammatory agents, muscle growth stimulators, gene editing therapies, immunomodulatory, and others. Among these, the muscle growth stimulators segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. This is due to muscle growth stimulators effectively enhancing muscle mass and strength, addressing both age-related and disease-induced muscle loss, and meeting increasing demand for therapies that improve patient mobility and quality of life.
North America is expected to hold the majority share of the global muscle wasting disorders market during the forecast period.
Get more details on this report -
North America is expected to account for the largest share of the global muscle wasting disorders market during the forecast period. This is due to high adoption of innovative therapies, extensive clinical trial activity, strong insurance coverage, and established pharmaceutical and biotech presence. Further, the U.S. is the leading country in the region’s muscle wasting disorders market, holding the largest regional share, owing to increased diagnostic rates of conditions such as Spinal Muscular Atrophy.
The Asia Pacific region is projected to witness the fastest growth, driven by the rapid adoption of innovative therapies, expanding clinical research programs, rising patient diagnosis rates, improving medical infrastructure, and increasing collaborations between local and global biotech companies. Japan is the leading country in the Asia Pacific muscle wasting disorders market, driven by the increasing healthcare expenditure and the adoption of innovative treatments.
Major vendors in the global muscle wasting disorders market are Pfizer Inc, F. Hoffmann La Roche Ltd, Novartis AG, Sanofi, GlaxoSmithKline, Eli Lilly and Company, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Biogen Inc, Santhera Pharmaceuticals, Sarepta Therapeutics, PTC Therapeutics, Ionis Pharmaceuticals, Cytokinetics Incorporated, Italfarmaco S p, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In March 2026, Biogen reported additional Phase 1b clinical trial data for its investigational antisense oligonucleotide therapy salanersen, for spinal muscular atrophy (SMA). The study showed about 75% reduction in neurofilament light chain (NfL) levels, a biomarker of neurodegeneration, and the company initiated a global Phase 3 clinical development program following these promising results.
- In April 2025, ProFuse Technology launched a new drug discovery platform focused on identifying therapies that prevent muscle loss. The platform targets conditions such as GLP-1 drug–associated muscle loss, cancer cachexia, and age-related sarcopenia, supporting development of treatments for muscle wasting disorders.
- In March 2024, for the treatment of Duchenne muscular dystrophy (DMD) in patients aged six years and older, making it the first nonsteroidal drug approved for all genetic variants of DMD. This approval expands treatment options for this progressive muscle wasting disorder and is directly relevant to the global muscle wasting disorders market.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the global muscle wasting disorders market based on the below-mentioned segments:
Global Muscle Wasting Disorders Market, By Disease Type
- Muscular Dystrophy
- Spinal Muscular Atrophy
- Amyotrophic Lateral Sclerosis
- Others
Global Muscle Wasting Disorders Market, By Treatment Modality
- Drug Therapies
- Gene Therapy
- Physical Therapy and Rehabilitation
- Supplements and Nutrition
- Others
Global Muscle Wasting Disorders Market, By Mechanism of Action
- Anti-Inflammatory Agents
- Muscle Growth Stimulators
- Gene Editing Therapies
- Immunomodulatory
- Others
Global Muscle Wasting Disorders Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?